Clifton Duane Kerr, MD in Tremonton, UT - General Practice

Clifton Duane Kerr, MD is a General Practice physician based in Tremonton, Utah. Clifton Duane Kerr is licensed to practice in Utah (license number 146197-1205) and his current practice location is 725 West 1000 North, Tremonton, Utah. He can be reached at his office (for appointments etc.) via phone at (435) 257-5542.

NPI number for Clifton Duane Kerr is 1740420835 and his current mailing address is 725 West 1000 North, Tremonton, Utah. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1740420835.

Contact Information

	Clifton Duane Kerr, MD
	725 West 1000 North, Tremonton, UT 84337
	(435) 257-5542
	Not Available

Physician's Profile

Full Name	Clifton Duane Kerr
Gender	Male
Speciality	General Practice
Location	725 West 1000 North, Tremonton, Utah
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1740420835
Provider Enumeration Date: 03/02/2009
Last Update Date: 03/02/2009

Medical Identifiers

Medical identifiers for Clifton Duane Kerr such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1740420835	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	146197-1205 (Utah)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Clifton Duane Kerr is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Clifton Duane Kerr, MD 725 West 1000 North, Tremonton, UT 84337 Ph: (435) 257-5542	Clifton Duane Kerr, MD 725 West 1000 North, Tremonton, UT 84337 Ph: (435) 257-5542

News Archive

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC).

Invida Group, Amdipharm partner to promote proprietary products in key Asian markets

Invida Group Pte Ltd, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has entered into an agreement with Amdipharm for the licensing and commercialization of its proprietary products throughout Asia. Under this agreement, Invida will leverage its full suite of capabilities to bring Amdipharm's products to market, from regulatory approval and licensing, through packaging and supply chain optimization, to commercialization, sales, and marketing.

Neuropathic pain features common in knee OA

Enough patients with knee osteoarthritis experience pain with neuropathic characteristics to warrant attempts to diagnose and classify these features, say researchers.

Regulating fas protein may be a route to prevent cancer relapse after immunotherapy

Mount Sinai researchers have solved one of the enduring mysteries of cancer immunotherapy: Why does it completely eliminate tumors in many patients, even when not all the cells in those tumors have the molecular target that the therapy is aimed at?

Plasma marker inflames schizophrenia risk

Elevated plasma levels of the inflammatory molecule C-reactive protein may be a marker of an increased risk for developing schizophrenia, a study suggests.

Clifton Duane Kerr, MD - General Practice in Tremonton, UT